Boiko, A N, Batysheva, T T, Matvievskaya, O V et al. · Neuroscience and behavioral physiology · 2007 · DOI
This study looked at why people with brain injuries (from multiple sclerosis, stroke, infection, or trauma) develop severe fatigue. Researchers tested 50 patients and gave half of them a medication called Fezam to see if it would help. The medication reduced fatigue symptoms, especially in MS patients, with few side effects.
This study examines neurobiological mechanisms of fatigue in acquired brain injury, which may provide insights into central mechanisms also relevant to ME/CFS. Understanding how different brain pathologies produce fatigue—and which treatments target specific underlying mechanisms—could inform therapeutic approaches for ME/CFS patients.
This study does not prove that Fezam is effective for ME/CFS, which has different etiology from post-injury fatigue. The absence of a control group means improvements could reflect placebo response, natural recovery, or reporting bias rather than drug efficacy. Correlation between fatigue and depression does not establish causation.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →